Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.
There is a great amount of excitement in the ovarian cancer clinical and research communities about the … Read more
Most – and possibly all – ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.
This is the finding of a multicenter study of ovarian cancer genetics led by researchers from Perlmutter Cancer Center … Read more
Don’t delay platinum-based chemotherapy in favor of single-agent non-platinum-based chemotherapy in patients with partially platinum-sensitive ovarian cancer, Italian researchers advised.
Introducing non-platinum chemotherapy to prolong the platinum-free interval (PFI) in patients with progressing ovarian cancer who experience disease recurrence, or … Read more
To better understand ovarian cancer, as well as predict when women might relapse, it is crucial that researchers start investigating more of the molecular phases of the disease, says Peter Dottino, M.D.
Studies are already underway in this area, and … Read more
More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments.
However, there is hope for such research to emerge. Ophira Ginsburg, M.D., director … Read more
In 2016, the American Cancer Society projected that the number of women dying worldwide from cancer was expected to rise to 5.5 million by 2030.1 In the realm of women’s cancers, ovarian cancer is prominent and serious. A woman … Read more
While precision medicine has been a modern go-to approach by physicians in various malignancies, it is demonstrating a particular benefit in ovarian cancer, especially using the method for clinical trial enrollment and in determining whether patients are eligible to receive … Read more
Women with ovarian cancer can safely stick to the standard 3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 … Read more
Administering niraparib to patients with recurrent ovarian cancer after a complete response (CR) or partial response (PR) to platinum-based chemotherapy may allow patients to continuously maintain their quality of life (QOL) during treatment, according to a study presented at the … Read more
Women with recurrent, platinum-sensitive ovarian cancer lived twice as long without disease progression when they received maintenance therapy with the PARP inhibitor rucaparib (Rubraca), a randomized trial showed.
Overall, patients treated with rucaparib had a median progression-free survival of 10.8 … Read more
Using a modern DNA sequencing technique, Johns Hopkins researchers have come one step closer to diagnosing early-stage cancer patients with a simple blood draw.
The method reads free circulating DNA in a patient’s blood and detects common cancer mutations. While … Read more
Despite the existence of evidence-based guidelines supporting genetic testing for women with a history of breast and/or ovarian cancer, most of these women didn’t get tested, according to researchers.
Based on an analysis of pooled data from three cancer control … Read more
Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance … Read more
If you’re a woman, there’s a good chance you’ve used Johnson’s Baby Powder at some point. It smells good, and it can keep you dry.
But is it dangerous?
Dr. Daniel Cramer says yes. He’s a professor of obstetrics and … Read more
Some of the most promising advances in cancer research in recent years involve treatments known as immunotherapy. These advances are spurring billions of dollars in investment by drug companies, and are leading to hundreds of clinical trials. Here are answers … Read more
On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete … Read more
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to … Read more
With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented in medical research.
There are too many experimental cancer drugs in too many clinical … Read more
In an effort to better group tumors into relevant targetable populations, investigators recently evaluated 4114 ovarian tumor specimens to identify the different molecular changes that can occur within the specimens, according to lead investigator, Julia A. Elvin, MD, PhD.
According … Read more
Patients who expressed a specific tumor antigen had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Cancer Institute researchers and published in the journal Gynecologic Oncology.… Read more
